The US Food and Drug
Administration (FDA) had a strong
2013 for approvals of novel drugs,
with 27 new molecular entities
(NMEs) approved.
This was about right for the
average of 26 approvals per year
since the beginning of this decade,
FD Center for Drug Evaluation
and Research Office of New Drugs
director John K. Jenkins said.
However, more important was the
quality of the drugs approved, and
the roles many of them could serve.
“We now have new safe and
effective treatments for a wide
range of serious medical conditions,
such as late-stage breast cancer,
chronic hepatitis C...and many
more.”
Highlights included that one third
of approved NMEs were “first-inclass.”The above article was sent to subscribers in Pharmacy Daily's issue from 04 Feb 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Feb 14
MEDICATION management platform MedAdvisor Limited (MDR) showed strong financial performance for the quarter concluded on 31 Mar 2024, with operating revenue up 42% to $24.2 million from $17 million for the same period last year.
PHARMACIES in regional areas need a restructure of the 8CPA Community Service Obligation (CSO) to help fund them to support their workforce and deliver services, says the Remote and Isolated Pharmacist Association Australia (RIPAA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.